The Experts below are selected from a list of 7038 Experts worldwide ranked by ideXlab platform
Ross C Smith - One of the best experts on this subject based on the ideXlab platform.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Background Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Samuel C L Kuo, Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed. Four PPoma patients who presented with nonspecific abdominal pain are described. Their diagnosis was established by the presence of an enhancing solitary Pancreatic tumor on computed tomography (CT) and elevated fasting Pancreatic Polypeptide hormone levels. Patient 1 was treated with a pancreatoduodenectomy because of elevation of serum CEA level. Two of the cases underwent enucleation because of prolonged stable CT appearance. Patient 4 underwent distal pancreatectomy for a Pancreatic neck tumor causing ductal obstruction and distal parenchymal atrophy. All cases had benign histological features apart from patient 1 whose tumor demonstrated occasional mitotic activity. These tumors have not recurred after a median of 49 (range, 35–57) months. The protein expression in the tumor tissue was measured by SELDI-TOF MS and was different than the profile of Pancreatic adenocarcinoma that was previously demonstrated in our laboratory. This may lead to future helpful diagnostic testing on fine needle aspirates. Resection of sporadic PPomas presenting as a solitary well-defined mass with benign histological features results in good long-term survival.
Stephen R Bloom - One of the best experts on this subject based on the ideXlab platform.
-
degradation paradigm of the gut hormone Pancreatic Polypeptide by hepatic and renal peptidases
Endocrinology, 2017Co-Authors: Joyceline Cuenco, Mohammad A Ghatei, James Minnion, Tricia Tan, Rebecca Scott, Natacha Germain, Yiin Ling, Rong Chen, Stephen R BloomAbstract:Pancreatic Polypeptide (PP) is a gut hormone that acts on Y4 receptors to reduce appetite. Obese humans display a reduced postprandial increase in PP and remain fully sensitive to the anorectic effects of exogenous PP. The utility of PP as an anti-obesity treatment is limited by its short circulating half-life. Insight into the mechanisms by which PP is degraded could aid in the design of long-acting PP analogs. We investigated the role of peptidases in PP degradation to determine whether inhibition of these enzymes enhanced PP plasma levels and bioactivity in vivo. Dipeptidyl peptidase IV (DPPIV) and neprilysin (NEP) were two peptidase found to cleave PP. Limiting the effect of both peptidases improved the in vivo anorectic effect of PP and PP-based analogs. These findings suggest that inhibiting the degradation of PP using specific inhibitors and/or the design of analogs resistant to cleavage by DPPIV and NEP might be useful in the development of PP as an anti-obesity pharmacotherapy.
-
Pancreatic Polypeptide meal response may predict gastric band induced weight loss
Obesity Surgery, 2011Co-Authors: Andrew Dixon, Mohammad A Ghatei, Stephen R Bloom, Carel Le W Roux, Toni L Mcgee, John DixonAbstract:Background Unknown hormonal and neural satiety signals are thought to drive sustainable weight loss following laparoscopic adjustable gastric banding (LAGB). The objective of this study was to investigate whether the structurally related satiety hormones Pancreatic Polypeptide (PP) and peptide YY (PYY) influence total percentage weight loss after LAGB.
-
low dose Pancreatic Polypeptide inhibits food intake in man
British Journal of Nutrition, 2007Co-Authors: David R Jesudason, Adrian Park, Mohammad A Ghatei, Gary Frost, Mariana P Monteiro, Barbara M Mcgowan, Nicola M Neary, Elena Philippou, C J Small, Stephen R BloomAbstract:Pancreatic Polypeptide (PP) is a gut hormone released from the pancreas in response to food ingestion and remains elevated for up to 6 h postprandially. Plasma levels are elevated in patients with Pancreatic tumours. An intravenous infusion of PP has been reported to reduce food intake in man, suggesting that PP is a satiety hormone. We investigated whether a lower infusion rate of PP would induce significant alterations in energy intake. The study was randomised and double-blinded. Fourteen lean fasted volunteers (five men and nine women) received 90 min infusions of PP (5 pmol/kg per min) and saline on two separate days. The dose chosen was half that used in a previous human study which reported a decrease in appetite but at supra-physiological levels of PP. One hour after the end of the infusion, a buffet lunch was served and energy intake measured. PP infusion was associated with a significant 11 % reduction in energy intake compared with saline (2440 (se 200) v. 2730 (se 180) kJ; P<0 x 05). Preprandial hunger as assessed by a visual analogue score was decreased in the PP-treated group compared to saline. These effects were achieved with plasma levels of PP within the pathophysiological range of Pancreatic tumours.
-
fat digestion is required for suppression of ghrelin and stimulation of peptide yy and Pancreatic Polypeptide secretion by intraduodenal lipid
American Journal of Physiology-endocrinology and Metabolism, 2005Co-Authors: Christine Feinlebisset, Michael Patterson, Mohammad A Ghatei, Stephen R Bloom, Michael HorowitzAbstract:Stimulation of cholecystokinin and glucagon-like peptide-1 secretion by fat is mediated by the products of fat digestion. Ghrelin, peptide YY (PYY), and Pancreatic Polypeptide (PP) appear to play a...
-
Pancreatic Polypeptide reduces appetite and food intake in humans
The Journal of Clinical Endocrinology and Metabolism, 2003Co-Authors: Rachel L Batterham, C Le W Roux, Sandra M Ellis, Mark Cohen, Adrian Park, Michael Patterson, Mohammad A Ghatei, Gary Frost, Stephen R BloomAbstract:Pancreatic Polypeptide (PP) is a gut hormone released from the pancreas in response to ingestion of food. Plasma PP has been shown to be reduced in conditions associated with increased food intake and elevated in anorexia nervosa. In addition peripheral administration of PP has been shown to decrease food intake in rodents. These findings suggest that PP may act as a circulating factor that regulates food intake. Therefore we investigated the effect of intravenous infusion of PP (10 pmol/kg/min) on appetite and food intake in a randomised double-blind placebo-controlled crossover study in ten healthy volunteers. Infusion of PP reduced appetite and decreased the energy intake at a buffet lunch two hours post-infusion by 21.8 ± 5.7% (P < 0.01). More importantly the inhibition of food intake was sustained, such that energy intake, as assessed by food diaries, was significantly reduced both the evening of the study and the following morning. Overall PP infusion reduced cumulative 24-hour energy intake by 25.3...
Ralph Santosoliveira - One of the best experts on this subject based on the ideXlab platform.
-
octreotide nanoparticles showed affinity for in vivo mia paca 2 inducted pancreas ductal adenocarcinoma mimicking Pancreatic Polypeptide secreting tumor of the distal pancreas ppoma
Pharmaceutical Research, 2019Co-Authors: Thais Ligiero Braga, Suyene Rocha Pinto, Sara Rhaissa Rezende Dos Reis, Filipe Leal Portilho, Aline Oliveira Da Silva De Barros, Emerson Soares Bernardes, Sofia Nascimento Dos Santos, Luciana Magalhaes Rebelo Alencar, Eduardo Riccijunior, Ralph SantosoliveiraAbstract:Purpose Pancreatic Polypeptide-secreting tumor of the distal pancreas (PPoma) is a rare, difficult and indolent type of cancer with a survival rate of 5-year in only 10% of all cases. The PPoma is classified as a neuroendocrine tumor (NET) not functioning that overexpresses SSTR 2 (somatostatin receptor subtype 2). Thus, in order to improve the diagnosis of this type of tumor, we developed nanoparticulate drug carriers based on poly-lactic acid (PLA) polymer loaded with octreotide and radiolabeled with Technetium-99 m (99mTc).
Sivakumar Gananadha - One of the best experts on this subject based on the ideXlab platform.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Background Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Samuel C L Kuo, Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed. Four PPoma patients who presented with nonspecific abdominal pain are described. Their diagnosis was established by the presence of an enhancing solitary Pancreatic tumor on computed tomography (CT) and elevated fasting Pancreatic Polypeptide hormone levels. Patient 1 was treated with a pancreatoduodenectomy because of elevation of serum CEA level. Two of the cases underwent enucleation because of prolonged stable CT appearance. Patient 4 underwent distal pancreatectomy for a Pancreatic neck tumor causing ductal obstruction and distal parenchymal atrophy. All cases had benign histological features apart from patient 1 whose tumor demonstrated occasional mitotic activity. These tumors have not recurred after a median of 49 (range, 35–57) months. The protein expression in the tumor tissue was measured by SELDI-TOF MS and was different than the profile of Pancreatic adenocarcinoma that was previously demonstrated in our laboratory. This may lead to future helpful diagnostic testing on fine needle aspirates. Resection of sporadic PPomas presenting as a solitary well-defined mass with benign histological features results in good long-term survival.
Anthony J Gill - One of the best experts on this subject based on the ideXlab platform.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Background Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed.
-
sporadic Pancreatic Polypeptide secreting tumors ppomas of the pancreas
World Journal of Surgery, 2008Co-Authors: Samuel C L Kuo, Sivakumar Gananadha, Christopher J Scarlett, Anthony J Gill, Ross C SmithAbstract:Sporadic Pancreatic neuroendocrine tumors, which predominantly secrete Pancreatic Polypeptide (PPoma), are rare and have not been associated with a clinical syndrome. A wider understanding of their pathological features and behavior is needed. Four PPoma patients who presented with nonspecific abdominal pain are described. Their diagnosis was established by the presence of an enhancing solitary Pancreatic tumor on computed tomography (CT) and elevated fasting Pancreatic Polypeptide hormone levels. Patient 1 was treated with a pancreatoduodenectomy because of elevation of serum CEA level. Two of the cases underwent enucleation because of prolonged stable CT appearance. Patient 4 underwent distal pancreatectomy for a Pancreatic neck tumor causing ductal obstruction and distal parenchymal atrophy. All cases had benign histological features apart from patient 1 whose tumor demonstrated occasional mitotic activity. These tumors have not recurred after a median of 49 (range, 35–57) months. The protein expression in the tumor tissue was measured by SELDI-TOF MS and was different than the profile of Pancreatic adenocarcinoma that was previously demonstrated in our laboratory. This may lead to future helpful diagnostic testing on fine needle aspirates. Resection of sporadic PPomas presenting as a solitary well-defined mass with benign histological features results in good long-term survival.
